$4.54
+0.12 (+2.71%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where NERV is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 3 with posted results
Held by 4 tracked-famous managers (Balyasny Asset Management L.P., MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, TWO SIGMA INVESTMENTS, LP) · FINRA short interest 15.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic MedicationsNCT07565428Change from Baseline to Week 12 in Marder Negative Symptoms Factor Score (NSFS)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: Roluperidone, risperidone, aripiprazole, olanzapine, Placebo | Negative Symptoms of Schizophrenia | 380 | Dec 2027 | ≤ 499 d | 2026-07-28 |
| A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of SchizophreniaNCT06107803results2025-03-26Extrapyramidal Symptoms Assessed by Abnormal Involuntary Movement Scale (AIMS) - Change From Baseline in AIMS Component MovementNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: Roluperidone 64 mg, Olanzapine 10 MG | Negative Symptoms in Schizophrenia | 17 | 2024-01-12actual | — | 2025-03-26 |
| Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of SchizophreniaNCT03397134results2023-04-28Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Placebo Oral Tablet, Roluperidone 32 mg, Roluperidone 64 mg | Negative Symptoms of Schizophrenia | 515 | 2020-05-26actual | — | 2023-04-28 |
| A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive DisorderNCT03446846results2020-12-17Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total ScoreRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MIN-117 5.0 mg, MIN-117 2.5 mg, Placebo | Major Depressive Disorder | 360 | 2019-11-21actual | — | 2020-12-17 |
| A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive MetabolizersNCT03072056Plasma PK parameter, CmaxNon-randomized · Open-label · Other | Phase 1 | Completed | Drug: MIN-101 | Healthy Subjects | 23 | 2017-07-07actual | — | 2017-08-31 |
| A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy SubjectsNCT03038646Part 1: Plasma PK parameter, CmaxRandomized · Open-label · Other | Phase 1 | Completed | Drug: MIN-101 | Healthy Subjects | 14 | 2017-04-20actual | — | 2017-08-31 |
| Pharmacokinetic Study of MIN-101 in Healthy SubjectsNCT02232529Part 1 Pharmacokinetic profile of MIN-101 and its main metabolites (AUC (0-last), Tmax, Cmax, AUC (0-inf), %AUCextrap, Lambda z, T1/2 and parent:metabolites ratioRandomized · Basic science | Phase 1 | Completed | Drug: MIN-101, Placebo | Schizophrenia | 32 | Feb 2015actual | — | 2015-02-24 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19